INDICATIONS FOR NEUTRON BEAM THERAPY

- Neutron beam treatment is indicated for salivary gland cancers that are inoperable, recurrent, or are resected with gross residual disease or positive margins.¹

- Other uses of Neutron Beam Therapy are considered investigational and therefore are not approved because its effectiveness for these indications has not been established.

BACKGROUND

Neutron Beam Therapy (NBT) is a type of radiation treatment that uses a particle accelerator so is not readily available in most of the country. Protons from the accelerator create a neutron beam that attacks cancer cells with more power than conventional radiation therapy. Neutrons are much heavier than photons, thus appear to be more effective in destroying very dense tumors. With neutron beam treatment, the risk of side effects on healthy tissue near the cancer site is greater, requiring equipment to precisely focus the beam and block exposure to any surrounding tissue. Currently, both the availability and the criteria for use are very limited.

Overview:

NBT has been employed mainly for the treatment of the salivary gland cancers. It has also been used to treat other malignancies such as soft tissue sarcoma, lung, pancreatic, colon, kidney, and prostate cancers. Nevertheless, NBT has not gained wide acceptance because of the clinical difficulty in generating neutron particles and limited publications.

The safety and efficacy of neutron beam radiation therapy has not been established in the published medical literature. Complication rates were increased for NBT compared to other forms of external beam radiation therapy, and questions remain with regard to patient selection criteria, technical parameters, and comparative efficacy to other treatment modalities.

¹ National Imaging Associates, Inc. (NIA) is a subsidiary of Evolent Health LLC.
**POLICY HISTORY**

<table>
<thead>
<tr>
<th>Date</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 2022</td>
<td>No Changes</td>
</tr>
<tr>
<td>February 2021</td>
<td>No Changes</td>
</tr>
<tr>
<td>February 2020</td>
<td>No Changes</td>
</tr>
<tr>
<td>February 2019</td>
<td>Added and updated references</td>
</tr>
</tbody>
</table>
REFERENCES


ADDITIONAL RESOURCES

Reviewed / Approved by NIA Clinical Guideline Committee
GENERAL INFORMATION
It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.

Disclaimer: National Imaging Associates, Inc. (NIA) authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Evolent Health LLC subsidiaries including, but not limited to, National Imaging Associates (“NIA”). The policies constitute only the reimbursement and coverage guidelines of NIA. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. NIA reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.